Kura Oncology Q3 net loss $38.6M; cash $452.6M; ziftomenib trial enrollment on track for mid-2024

Kura Oncology, Inc.

2023-Q3 EPS reported -$1.53

Net loss $38.6M vs $35.5M YoY; R&D $29.3M; cash $452.6M provides runway to mid-2026.
Enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete 85 patients by mid-2024.
Preliminary data from 20 patients in KOMET-007 combination trial (ziftomenib + venetoclax/azacitidine or 7+3) expected early Q1 2024.
First patient dosed in FIT-001 trial of next-gen FTI KO-2806; collaboration with Mirati for combo with adagrasib in KRAS G12C-mutated NSCLC.
Brian Powl appointed Chief Commercial Officer in August 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kura Oncology, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023 and providing a corporate update.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-058157

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.